300142 沃森生物
已收盘 08-20 15:00:00
资讯
新帖
简况
8月20日沃森生物创60日新高,招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 16:41
8月20日沃森生物创60日新高,招商国证生物医药指数(LOF)C基金重仓该股
生物疫苗股全线大涨,康希诺等5股20CM涨停,默沙东莫德纳黑色素瘤疫苗临床试验传捷报
格隆汇 · 09:47
生物疫苗股全线大涨,康希诺等5股20CM涨停,默沙东莫德纳黑色素瘤疫苗临床试验传捷报
四大指数集体高开!生物医药板块大爆发,康希诺、沃森生物一字20CM涨停,农业、煤炭板块下跌|开盘播报
每日经济新闻 · 09:38
四大指数集体高开!生物医药板块大爆发,康希诺、沃森生物一字20CM涨停,农业、煤炭板块下跌|开盘播报
沃森生物:您所提到的中标信息属实
证券之星 · 08-18 11:36
沃森生物:您所提到的中标信息属实
沃森生物:公司九价HPV疫苗目前处于III期临床研究阶段
证券之星 · 08-18 11:36
沃森生物:公司九价HPV疫苗目前处于III期临床研究阶段
沃森生物(300142)披露调整第六届董事会专门委员会组成人员公告,8月17日股价上涨0.15%
证券之星 · 08-17 22:05
沃森生物(300142)披露调整第六届董事会专门委员会组成人员公告,8月17日股价上涨0.15%
股市必读:沃森生物新发布《关于召开2026年第四次临时股东会的提示性公告》
证券之星 · 08-17
股市必读:沃森生物新发布《关于召开2026年第四次临时股东会的提示性公告》
沃森生物(300142)披露召开2026年第四次临时股东大会通知,8月13日股价上涨1.22%
证券之星 · 08-13
沃森生物(300142)披露召开2026年第四次临时股东大会通知,8月13日股价上涨1.22%
沃森生物(300142)披露2026年第三次临时股东会决议公告,8月12日股价下跌0.23%
证券之星 · 08-12
沃森生物(300142)披露2026年第三次临时股东会决议公告,8月12日股价下跌0.23%
沃森生物:公司九价HPV疫苗目前处于III期临床研究阶段
证券之星 · 08-07
沃森生物:公司九价HPV疫苗目前处于III期临床研究阶段
沃森生物:持续推进疫苗海外注册和出口业务
证券之星 · 08-07
沃森生物:持续推进疫苗海外注册和出口业务
沃森生物新提交“-”、“沃云臻”等4件商标注册申请
证券之星 · 08-07
沃森生物新提交“-”、“沃云臻”等4件商标注册申请
沃森生物(300142)披露召开2026年第三次临时股东会提示性公告,8月6日股价下跌3.03%
证券之星 · 08-06
沃森生物(300142)披露召开2026年第三次临时股东会提示性公告,8月6日股价下跌3.03%
沃森生物:公司九价HPV疫苗目前处于III期临床研究阶段
证券之星 · 08-04
沃森生物:公司九价HPV疫苗目前处于III期临床研究阶段
沃森生物:调增2026年度向特定对象发行A股股票募集资金总额
证券之星 · 08-04
沃森生物:调增2026年度向特定对象发行A股股票募集资金总额
沃森生物:不存在资金链断裂的风险
证券之星 · 08-04
沃森生物:不存在资金链断裂的风险
沃森生物拟通过非公开发行股票募资最多22亿元,用于补充资本
美股速递 · 08-03
沃森生物拟通过非公开发行股票募资最多22亿元,用于补充资本
沃森生物:拓宽中长期直接融资渠道
证券之星 · 07-28
沃森生物:拓宽中长期直接融资渠道
沃森生物:2026年度向特定对象发行A股股票按计划推进
证券之星 · 07-28
沃森生物:2026年度向特定对象发行A股股票按计划推进
7月24日沃森生物跌9.95%,招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 07-24
7月24日沃森生物跌9.95%,招商国证生物医药指数(LOF)C基金重仓该股
暂无数据
公司概况
公司名称:
云南沃森生物技术股份有限公司
所属行业:
医药制造业
上市日期:
2010-11-12
主营业务:
云南沃森生物技术股份有限公司的主营业务是人用疫苗等生物技术药的研发、生产和销售。公司的主要产品是13价肺炎结合疫苗、双价HPV疫苗、23价肺炎多糖疫苗、b型流感嗜血杆菌结合疫苗、A群C群脑膜炎球菌多糖结合疫苗、ACYW135群脑膜炎球菌多糖疫苗、A群C群脑膜炎球菌多糖疫苗、吸附无细胞百白破联合疫苗。公司是中国首家、全球第二家自主研发并成功上市13价肺炎结合疫苗的企业,也是中国第二家、全球第四家自主研发并成功上市HPV疫苗的企业。
发行价格:
95.00
{"stockData":{"symbol":"300142","market":"SZ","secType":"STK","nameCN":"沃森生物","latestPrice":15.12,"timestamp":1787209389000,"preClose":12.6,"halted":0,"volume":67088391,"delay":0,"changeRate":0.2,"floatShares":1577000000,"shares":1599000000,"eps":0.1787,"marketStatus":"已收盘","change":2.52,"latestTime":"08-20 15:00:00","open":15.12,"high":15.12,"low":15.12,"amount":1014000000,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":15.12,"bidSize":532784,"shortable":0,"etf":0,"ttmEps":0.1787,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787275800000},"marketStatusCode":5,"adr":0,"adjPreClose":12.6,"symbolType":"stock","openAndCloseTimeList":[[1787189400000,1787196600000],[1787202000000,1787209200000]],"highLimit":13.86,"lowLimit":11.34,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1599348541,"isCdr":false,"pbRate":2.72,"roa":"--","peRate":84.61108,"roe":"1.41%","epsLYR":0.1111,"committee":0,"marketValue":24182000000,"turnoverRate":0.0425,"status":0,"floatMarketCap":23843000000},"requestUrl":"/m/hq/s/300142/tweets","defaultTab":"tweets","newsList":[{"id":"2660066402","title":"8月20日沃森生物创60日新高,招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660066402","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660066402?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:41","pubTimestamp":1787215318,"startTime":"0","endTime":"0","summary":"证券之星消息,8月20日沃森生物涨20.00%创60日新高,收盘报15.12元,换手率4.25%,成交量67.09万手,成交额10.14亿元。重仓沃森生物的前十大公募基金请见下表:根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共14家,其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000028979.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399441","BK0077","BK0239","BK0046","BK0070","300142","161726"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660727484","title":"生物疫苗股全线大涨,康希诺等5股20CM涨停,默沙东莫德纳黑色素瘤疫苗临床试验传捷报","url":"https://stock-news.laohu8.com/highlight/detail?id=2660727484","media":"格隆汇","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660727484?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:47","pubTimestamp":1787190439,"startTime":"0","endTime":"0","summary":"8月20日,A股市场生物疫苗股全线大涨,其中,百克生物、康希诺、沃森生物、莱美药业、智飞生物20CM涨停,康华生物逼近20CM涨停,康泰生物涨超17%,华兰疫苗涨超10%,德展健康、双鹭药业、海普瑞、海欣股份、万泰生物10CM涨停,金迪克、博晖创新涨超7%,西藏药业、卫光生物、利德曼、冠昊生物、塞力医疗、赛升药业、申联生物、欧林生物涨超6%。消息面上,默沙东与莫德纳周三宣布,联合研发的黑色素瘤皮肤癌疫苗在首次晚期临床试验中取得积极初步结果。\n\n港股频道更多独家策划、专家专栏,免费查阅>>\n\n 责任编辑:栎树","market":"hk","thumbnail":"http://imgcloud.jrjimg.cn/2026/08/cms_20260820094719181.jpg","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2026/08/cms_20260820094719181.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/08/20094758182842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IE00BLSP4239.USD","688185","IE0009355771.USD","LU0689626769.HKD","LU2491050071.SGD","BK4501","LU2023250843.SGD","LU0098860793.USD","301207","LU0861579265.USD","LU0942090050.USD","LU1989772840.SGD","XLV","LU0130102774.USD","LU1571399168.USD","LU1023059063.AUD","BK0077","IE00BJJMRZ35.SGD","LU0211331839.USD","LU1989771016.USD","LU1585245621.USD","LU0868494617.USD","LU0965509283.SGD","BK4550","LU0234572021.USD","LU0965508806.USD","LU2023250504.SGD","LU1066051498.USD","SG9999001440.SGD","LU1064131003.USD","LU2125909593.SGD","LU1291159041.SGD","LU1941712348.USD","LU2361044865.SGD","IE00BN8TJ469.HKD","LU0124676726.USD","VHT","LU1061106388.HKD","FTXH","LU1037948897.HKD","BK4139","LU1066051225.USD","LGHT","LU2148510915.USD","IE00BJT1NW94.SGD","HRTS","LU0859254822.USD","IE00B2B36J28.USD","LU2361045086.USD","LU1064130708.USD","IDNA","LU0070302665.USD","RXL","BK4585","LU1430594728.SGD","LU1057294990.SGD","LU1917777945.USD","LU0965509010.AUD","BK4588","LU1093756168.USD","LU0265550359.USD","LU0006306889.USD","LU0122379950.USD","GDOC","LU1116320737.USD","BK4568","LU1069347547.HKD","BK4551","LU0320765646.SGD","LU1699723380.USD","LU2361044949.HKD","SGXZ57979304.SGD","TRUH","JDOC","LU2491050154.USD","300142","BK0196","LU0985320562.USD","LU2106854487.HKD","LU2580892862.HKD","SG9999014567.USD","LU1989772923.USD","LU2491049909.HKD","LU1934455863.HKD","FHLC","LU1116320901.HKD","300122","IE00B4R5TH58.HKD","LU2089984988.USD","MRNX","06185","SG9999014559.SGD","LU0868494708.USD","BK4533","LU1066053197.SGD","LU0823416689.USD","LU0203347892.USD","LU1328615791.USD","LU2357627491.SGD","IXJ","LU0266013472.USD","LU2125154778.USD","LU2125154935.USD","SG9999015358.SGD","LU2433249047.HKD","LU0208291251.USD","SG9999001176.SGD","LU1934455194.USD","WDNA","SG9999002232.USD","SG9999014542.SGD","LU0289739699.SGD","LU1066051811.HKD","LU2324357040.USD","688276","LU1941712264.USD","MRNA","LU0432979614.USD","LU2112291526.USD","LU0980610538.SGD","IE00BBT3K403.USD","PPH","LU0130517989.USD","PAWZ","SG9999001176.USD","BK0239","SG9999013999.USD","LU0477156953.USD","LU1035773651.USD","IE00B1BXHZ80.USD","BK4534","LU1929549753.HKD","LU1093756325.SGD","LU0648001328.SGD","SG9999002224.SGD","BK4548","IE00BSNM7G36.USD","BK4516","GNOM","IHE","LU1162221912.USD","LU1923622614.USD","BK0070","300006","LU1934455277.USD","LU2360032135.SGD","SG9999015341.SGD","IE0002141913.USD","LU0320765489.SGD","LU0203345920.USD","LU0058720904.USD","BK4559","LU0965509101.SGD","BK0188","LU1974910355.USD","LU0265550946.USD","LU2125909247.SGD","LU2580892789.USD","MRNY","LU2468319806.SGD","LU0106261372.USD","LU1983299246.USD","IE00BFTCPJ56.SGD","MRK","SG9999014575.USD","IE00BLSP4452.SGD","IYH","BK0046","BK4532","LU2461242641.AUD","LU0238689110.USD","LU1037948541.HKD","LU1201861249.SGD","IE000M9KFDE8.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660472123","title":"四大指数集体高开!生物医药板块大爆发,康希诺、沃森生物一字20CM涨停,农业、煤炭板块下跌|开盘播报","url":"https://stock-news.laohu8.com/highlight/detail?id=2660472123","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660472123?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:38","pubTimestamp":1787189887,"startTime":"0","endTime":"0","summary":"8月20日,A股主要指数集体高开,上证指数高开0.33%,深证成指高开1.03%,创业板指高开1.27%,科创综指高开1.35%。生物医药板块爆发,创新药、ADC、基因检测、CRO方向领涨,贵金属板块表现亮眼;农业、煤炭板块表现低迷。消息面上,昨夜美股纳斯达克生物科技指数大涨6.4%,创下六年来最大涨幅;Moderna飙升176%,市值增加440亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608203847305243.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608203847305243.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["399441","BK0046","161726","XBI","159041","BK4585","BK0239","BK0070","BK0077","300142","BK4581","161032","BK4588","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660594074","title":"沃森生物:您所提到的中标信息属实","url":"https://stock-news.laohu8.com/highlight/detail?id=2660594074","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660594074?lang=zh_cn&edition=full","pubTime":"2026-08-18 11:36","pubTimestamp":1787024201,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物(300142)08月18日在投资者关系平台上答复投资者关心的问题。投资者提问:在2026年7月6日发布的《2026年国家免疫规划疫苗集中采购项目-项目采购第六批中标公告》中,沃森生物旗下的玉溪沃森生物技术有限公司作为第4包的中标供应商,中标金额为2344.938160万元,是否属实,是A 群C群脑膜炎球菌多糖疫苗疫苗吗沃森生物回复:尊敬的投资者,您好!您所提到的中标信息属实。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800016277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300142","BK0239","BK0046","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660459233","title":"沃森生物:公司九价HPV疫苗目前处于III期临床研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2660459233","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660459233?lang=zh_cn&edition=full","pubTime":"2026-08-18 11:36","pubTimestamp":1787024193,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物08月18日在投资者关系平台上答复投资者关心的问题。国产九价HPV 2026-2027年迎集中获批窗口,万泰、瑞科紧追,公司九价处于Ⅲ期临床阶段。预计2026年还是2027年哪个季度正式提交NDA?公司九价HPV疫苗目前处于III期临床研究阶段,公司将按照国家对于疫苗注册临床试验的有关程序和要求推进在研疫苗产品的相关工作,有关信息请持续关注公司后续披露的公告和定期报告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800016264.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0239","BK0077","BK0070","BK0046","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660433433","title":"沃森生物(300142)披露调整第六届董事会专门委员会组成人员公告,8月17日股价上涨0.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660433433","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660433433?lang=zh_cn&edition=full","pubTime":"2026-08-17 22:05","pubTimestamp":1786975538,"startTime":"0","endTime":"0","summary":"截至2026年8月17日收盘,沃森生物报收于13.3元,较前一交易日上涨0.15%,最新总市值为212.71亿元。该股当日开盘13.3元,最高13.39元,最低12.98元,成交额达7.21亿元,换手率为3.46%。近日,沃森生物披露《关于调整第六届董事会专门委员会组成人员的公告》。因独立董事王英典当选、赵健梅任期届满离任,公司对审计委员会、提名委员会、薪酬与考核委员会、可持续发展委员会成员进行调整,战略委员会组成不变。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700034831.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0077","BK0239","300142","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660177006","title":"股市必读:沃森生物新发布《关于召开2026年第四次临时股东会的提示性公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660177006","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660177006?lang=zh_cn&edition=full","pubTime":"2026-08-17 01:05","pubTimestamp":1786899912,"startTime":"0","endTime":"0","summary":"公司公告汇总:沃森生物将于8月19日召开2026年第四次临时股东会,审议调增向特定对象发行A股募集资金总额等特别决议事项,关联股东需回避表决。公司公告汇总关于召开2026年第四次临时股东会的提示性公告云南沃森生物技术股份有限公司将于2026年8月19日召开2026年第四次临时股东会,会议采取现场表决与网络投票相结合方式。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700000407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0077","BK0239","300142","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659168927","title":"沃森生物(300142)披露召开2026年第四次临时股东大会通知,8月13日股价上涨1.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659168927","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659168927?lang=zh_cn&edition=full","pubTime":"2026-08-13 22:09","pubTimestamp":1786630159,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘,沃森生物报收于13.32元,较前一交易日上涨1.22%,最新总市值为213.03亿元。该股当日开盘13.12元,最高13.56元,最低12.92元,成交额达12.96亿元,换手率为6.16%。近日,沃森生物发布《关于召开2026年第四次临时股东会的提示性公告》。公告显示,公司将于2026年8月19日召开2026年第四次临时股东会,会议采取现场表决与网络投票相结合方式。股权登记日为2026年8月12日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300039512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0077","BK0070","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658390393","title":"沃森生物(300142)披露2026年第三次临时股东会决议公告,8月12日股价下跌0.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658390393","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658390393?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:05","pubTimestamp":1786543519,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘,沃森生物报收于13.16元,较前一交易日下跌0.23%,最新总市值为210.47亿元。该股当日开盘13.18元,最高13.4元,最低13.07元,成交额达7.27亿元,换手率为3.49%。近日,云南沃森生物技术股份有限公司发布《2026年第三次临时股东会决议公告》。出席会议股东及股东代理人共1,155人,代表股份占公司总股本的13.7328%。本次会议召集、召开程序合法合规,表决结果合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200039937.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0070","300142","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657667364","title":"沃森生物:公司九价HPV疫苗目前处于III期临床研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2657667364","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657667364?lang=zh_cn&edition=full","pubTime":"2026-08-07 08:54","pubTimestamp":1786064073,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物(300142)08月06日在投资者关系平台上答复投资者关心的问题。投资者提问:近期沃森生物的9价HPV能否提速一下???让更多的女孩子享受9价HPV带来的健康沃森生物回复:尊敬的投资者,您好!非常感谢您对公司的关注和建议。公司九价HPV疫苗目前处于III期临床研究阶段,公司将按照国家对于疫苗注册临床试验的有关程序和要求推进在研疫苗产品的相关工作,有关信息请持续关注公司后续披露的公告和定期报告。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700008271.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","159646","BK0070","300142","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657673336","title":"沃森生物:持续推进疫苗海外注册和出口业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2657673336","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657673336?lang=zh_cn&edition=full","pubTime":"2026-08-07 08:54","pubTimestamp":1786064071,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物(300142)08月06日在投资者关系平台上答复投资者关心的问题。投资者提问:6月与哈萨克斯坦Gold Astrum LLC签署的疫苗商业化合作备忘录,近期可计划对其出口沃森生物回复:尊敬的投资者,您好!公司持续加强与全球健康组织和海外生物药企的交流与合作,采取多元化合作模式,深入推进产品在海外市场的注册和出口业务,不断拓展海外市场合作的深度和广度,为公司和股东创造价值。关于公司出口疫苗产品的具体信息请以公司披露的公告为准,请持续关注。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700008269.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0070","BK0046","BK0077","300142","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657666121","title":"沃森生物新提交“-”、“沃云臻”等4件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2657666121","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657666121?lang=zh_cn&edition=full","pubTime":"2026-08-07 07:08","pubTimestamp":1786057705,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示,近日云南沃森生物技术股份有限公司新提交“-”、“沃云臻”等4件商标注册申请。商标申请详情如下:今年以来云南沃森生物技术股份有限公司新申请注册商标86件,截止目前公司共持有注册商标330件,另有170件商标尚在注册申请中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700006106.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0070","300142","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657963086","title":"沃森生物(300142)披露召开2026年第三次临时股东会提示性公告,8月6日股价下跌3.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657963086","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657963086?lang=zh_cn&edition=full","pubTime":"2026-08-06 22:06","pubTimestamp":1786025184,"startTime":"0","endTime":"0","summary":"截至2026年8月6日收盘,沃森生物报收于12.18元,较前一交易日下跌3.03%,最新总市值为194.8亿元。该股当日开盘12.5元,最高12.53元,最低12.09元,成交额达7.6亿元,换手率为3.94%。近日,云南沃森生物技术股份有限公司发布《关于召开2026年第三次临时股东会的提示性公告》。公告显示,公司将于2026年8月12日召开2026年第三次临时股东会,会议采取现场与网络投票相结合方式,股权登记日为2026年8月5日。中小投资者表决将单独计票。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600039686.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300142","BK0077","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656535843","title":"沃森生物:公司九价HPV疫苗目前处于III期临床研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2656535843","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656535843?lang=zh_cn&edition=full","pubTime":"2026-08-04 15:57","pubTimestamp":1785830230,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物08月04日在投资者关系平台上答复投资者关心的问题。国产九价HPV赛道2026—2027年将迎来集中获批窗口期,公司九价HPV目前处于Ⅲ期临床研究阶段。③预计2026年或2027年哪个季度正式提交NDA?公司九价HPV疫苗目前处于III期临床研究阶段,公司将按照国家对于疫苗注册临床试验的有关程序和要求推进在研疫苗产品的相关工作,相关信息请持续关注公司后续披露的公告和定期报告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400024156.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0070","BK0046","BK0077","BK0239","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656538443","title":"沃森生物:调增2026年度向特定对象发行A股股票募集资金总额","url":"https://stock-news.laohu8.com/highlight/detail?id=2656538443","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656538443?lang=zh_cn&edition=full","pubTime":"2026-08-04 15:12","pubTimestamp":1785827540,"startTime":"0","endTime":"0","summary":"2026年8月3日,公司第六届董事会第七次会议审议通过了《关于调增公司2026年度向特定对象发行A股股票募集资金总额暨调整发行方案的议案》等与本次发行相关的议案,对本次发行的募集资金总额、定价基准日、发行价格及发行数量进行了调整,并于8月4日在巨潮资讯网披露了调整发行方案的公告、本次发行的预案(修订稿)、发行方案论证分析报告(修订稿)等公告,敬请投资者查阅。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400020139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300142","BK0077","BK0046","159982","BK0239","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656538459","title":"沃森生物:不存在资金链断裂的风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2656538459","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656538459?lang=zh_cn&edition=full","pubTime":"2026-08-04 15:12","pubTimestamp":1785827539,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物08月04日在投资者关系平台上答复投资者关心的问题。公司目前生产经营正常,不存在资金链断裂的风险,相关财务数据请查阅公司已披露的定期报告。本次调整后的发行方案尚需经公司股东会审议通过,在获得深圳证券交易所审核通过并经中国证监会同意注册等必需的行政审批后方可实施。本次发行能否最终获得中国证监会同意注册尚存在不确定性,敬请投资者关注相关风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400020138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0046","BK0077","300142","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142107601","title":"沃森生物拟通过非公开发行股票募资最多22亿元,用于补充资本","url":"https://stock-news.laohu8.com/highlight/detail?id=1142107601","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142107601?lang=zh_cn&edition=full","pubTime":"2026-08-03 20:14","pubTimestamp":1785759248,"startTime":"0","endTime":"0","summary":"沃森生物(Walvax Biotechnology Co., Ltd.)宣布,计划通过非公开发行股票的方式,募集最高达22亿元人民币的资金。此举旨在进一步充实公司的资本实力,以满足其业务发展需求。据悉,此次募资将主要用于补充流动资金及改善财务状况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0046","BK0070","BK0239","300142","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654074167","title":"沃森生物:拓宽中长期直接融资渠道","url":"https://stock-news.laohu8.com/highlight/detail?id=2654074167","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654074167?lang=zh_cn&edition=full","pubTime":"2026-07-28 15:57","pubTimestamp":1785225425,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物07月28日在投资者关系平台上答复投资者关心的问题。公司2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中,本次发行后续还需要经深圳证券交易所审核通过并经中国证监会同意注册等必需的行政审批后方可实施,关于项目的相关信息请以公司披露的公告为准,请持续关注。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800022861.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0046","BK0077","300142","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654020956","title":"沃森生物:2026年度向特定对象发行A股股票按计划推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2654020956","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654020956?lang=zh_cn&edition=full","pubTime":"2026-07-28 11:38","pubTimestamp":1785209896,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物07月27日在投资者关系平台上答复投资者关心的问题。现在证监会已经不允许固定价格定增了,当初设定9.6的定增价格是否正常沃森生物回复:尊敬的投资者,您好!公司2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中。本次发行后续还需要经深圳证券交易所审核通过并经中国证监会同意注册等必需的行政审批后方可实施。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800015979.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","159982","BK0046","399300","BK0070","300142","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653700911","title":"7月24日沃森生物跌9.95%,招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653700911","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653700911?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:51","pubTimestamp":1784883068,"startTime":"0","endTime":"0","summary":"重仓沃森生物的前十大公募基金请见下表:根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共14家,其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C目前规模为15.39亿元,最新净值0.3974,较上一交易日下跌0.5%,近一年下跌3.29%。招商国证生物医药指数C的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400028926.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161726","300142","BK0077","BK0046","BK0070","399441","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787225563790,"stockEarnings":[{"period":"1week","weight":-0.0426},{"period":"1month","weight":-0.0476},{"period":"3month","weight":-0.0737},{"period":"6month","weight":0.0624},{"period":"1year","weight":-0.0252},{"period":"ytd","weight":0.1696}],"compareEarnings":[{"period":"1week","weight":-0.0132},{"period":"1month","weight":0.0259},{"period":"3month","weight":-0.0448},{"period":"6month","weight":-0.046},{"period":"1year","weight":0.0448},{"period":"ytd","weight":-0.0188}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"云南沃森生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"118448人(较上一季度减少0.27%)","perCapita":"13313股","listingDate":"2010-11-12","address":"云南省昆明市五华区高新区科新路395号","registeredCapital":"159934万元","survey":" 云南沃森生物技术股份有限公司的主营业务是人用疫苗等生物技术药的研发、生产和销售。公司的主要产品是13价肺炎结合疫苗、双价HPV疫苗、23价肺炎多糖疫苗、b型流感嗜血杆菌结合疫苗、A群C群脑膜炎球菌多糖结合疫苗、ACYW135群脑膜炎球菌多糖疫苗、A群C群脑膜炎球菌多糖疫苗、吸附无细胞百白破联合疫苗。公司是中国首家、全球第二家自主研发并成功上市13价肺炎结合疫苗的企业,也是中国第二家、全球第四家自主研发并成功上市HPV疫苗的企业。","listedPrice":95},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"沃森生物(300142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供沃森生物(300142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"沃森生物,300142,沃森生物股票,沃森生物股票老虎,沃森生物股票老虎国际,沃森生物行情,沃森生物股票行情,沃森生物股价,沃森生物股市,沃森生物股票价格,沃森生物股票交易,沃森生物股票购买,沃森生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"沃森生物(300142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供沃森生物(300142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}